← Leaderboards
Qijing Li
Duke University
$4,973,474
Attributed
$7,806,999
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2011–22$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,806,999 · 7
By mechanism
R01$5,882,426 · 5
R33$1,540,837 · 1
R56$383,736 · 1
Top collaborators
- Xiao-Fan Wang7 shared
- John H Sampson2 shared
- David M. Ashley1 shared
Most similar at Duke University
Same institution · by research overlap
- Xiao-Fan Wang$23,927,835
- John H Sampson$43,413,436
- David Reardon$8,732,934
- G Greg Wang$11,565,583
- Tereza Martinu$936,754
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingNeoplastic CellCellsT-LymphocyteResponseMalignant NeoplasmsMolecularImmuneImmune SystemNovel TherapeuticsInhibitor/AntagonistT-Cell ActivationCombatGenesTumor MicroenvironmentEpigenetic ProcessPathway InteractionsCancer TherapyImmune ResponseImmunotherapyBaseAntigensPreclinical EfficacyRegulation
Grant awards (16)
Clinical Neuroimmunology of Vaccines in Brain Tumors$400,733
R01 · FY2022 · NS
Synthetic lethality by targeting the core senescent mechanism in lung cancer.$490,590
R01 · FY2021 · CA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma$469,848
R01 · FY2021 · CA
Targeting UHRF1 in combinational immunotherapy$468,277
R01 · FY2021 · CA
Clinical Neuroimmunology of Vaccines in Brain Tumors$400,801
R01 · FY2021 · NS
Synthetic lethality by targeting the core senescent mechanism in lung cancer.$497,781
R01 · FY2020 · CA
Targeting UHRF1 in combinational immunotherapy$468,148
R01 · FY2020 · CA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma$456,286
R01 · FY2020 · CA
Targeting UHRF1 in combinational immunotherapy$473,749
R01 · FY2019 · CA
Area A: Development of genetically tractable, driver gene-syngeneic brain tumor models for pre-clinical adoptive TCR-T therapy$1,540,837
R33 · FY2017 · CA · contact PI
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity$381,037
R01 · FY2016 · AI · contact PI
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity$381,478
R01 · FY2015 · AI · contact PI
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity$381,902
R01 · FY2014 · AI · contact PI
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity$359,387
R01 · FY2013 · AI · contact PI
Regulatory mechanisms of miR-19b, a novel mediator of T cell autoimmunity$252,409
R01 · FY2012 · AI · contact PI
Harnessing microRNAs within miR-17-92 cluster for autoimmune intervention$383,736
R56 · FY2011 · AI · contact PI